Annals of Oncology 1993: Vol 4 Index

15 Pages·1993·3.5 MB·English

Annals of Oncology 4: 899-908, 1993.
Index of subjects Volume 4 (1993)
A anticancer drugs
acquired immune deficiency syndrome and biochemical modulation 277
and HD 621, 635 and relevance of pharmacokinetics 463, 465, 466
adenocarcinomas of unknown origin based on DNA topoisomerases as target 533
phase II study of oral etoposide 789 p53 as a target of 623
adenoid cystic carcinoma role of dose intensity 349, 351, 377
phase II of epirubicin in the treatment of 785 taxotere in experimental ovarian cancer 321
adhesion molecules ten years later: epirubicin 359
cellular recognition mechanism 545 antifolate
adjuvant therapy edatrexate in melanoma 254
for breast cancer 295 modulation with leucovorin stereoisomers $2: |
for colorectal cancer $2: 21 astrocytoma (see glioma)
adriamycin (see doxorubicin) autologous bone marrow transplantation
adverse drug reactions comparison with conventional salvage treatment in Hodgkin’s
of taxotere, preventive treatment 610 disease 385
ophthalmic complications with carboplatin 337 gonadal function after 399
unexpected fatal toxicity with low dose leucovorin/5-FU 174 in aggressive lymphoma $1: 7
with tamoxifen 683 in breast cancer 351
AIDS in Hodgkin’s disease 767, 889
and Hodgkin’s disease 621, 635 in low-grade lymphoma S1: 1
ALL (see also leukemia) in relapsed Hodgkin’s disease 889, $1: 21
role of ABMT in adults S1: 81 in solid tumors $1: 29
allergic reactions in solid tumors of childhood $1: 45
to taxotere, preventive treatment 610 in the primary treatment of Hodgkin’s disease S1: 15
alpha-interferon (see interferons) in the treatment of ALL S1: 81
alternative therapies in the treatment of AML S1: 59
and quality-of-life in cancer patients 121
AML (see also ieukemia) B
increased incidence of childhood acute promyelocytic bel-2
leukemia in Nicaragua 892 clinical relevance 51
relapse presenting as bone chloroma 339 rearrangement 51
role of ABMT S1: 59 biochemical modulation
secondary forms after etoposide treatment 559 as a model in solid tumors 277
anemia 5-FU-a-IFN monitored by magnetic resonance 597
treatment with erythropoietin in tumors 161 meta-analysis of trials involving 5-FU and leucovorin $2: 15
aneuploidy fraction of 5-FU by oral uridine 317
and DNA index as prognostic factors in breast cancer 643 sequential methotrexate, 5-FU and leucovorin vs. 5-FU and
role of ploidy in ovarian carcinoma S4: 3 leucovorin 235
anthracyclines with stereoisomers of leucovorin $2: 1, $2: 7, $2: 29
epirubicin and ifosfamide in soft tissue sarcomas 669 biological response modifiers
epirubicin in adenoid cystic carcinoma 785 after high-dose cyclophosphamide 759
epirubicin in breast cancer 45 and oncogenes 35
epirubicin ten years later 359 and phase I trials methodology 471
epirubicin vs. doxorubicin 359 as a continuous infusion in renal cell cancer 689
in continuous infusion 723 for malignant pleural effusions 141
increased dose-intensity in breast cancer 351 in ovarian cancer $4: 71, S4: 83
anti-emetic therapy in the treatment of non-Hodgkin’s lymphoma 182, 205
the state-of-the-art 443, 794 intrapleural instillation 141
anti-emetic(s) modulation of 5-FU monitored by magnetic resonance 597
current issues in their management S3: 3 urinary-derived P-i00 877
early trial of MDL 73.147 EF: a new 5-HT,-receptors with 5-FU and leucovorin in pancreatic cancer 83
antagonist 481 biology
oral ondansetron in patients treated with CMF 475 of breast cancer 643
pharmacology of tropisetron S3: 15 of cytokines 35
review of experiences with ondansetron and granisetron $3: 9 of ovarian cancer 775, S4: 3
role of tropisetron S3: 1 bladder cancer
should 5-HT, antagonists be first line therapy? 433, 434 bladder preservation with front-line chemotherapy 147
state-of-the-art 443, 793 chemotherapy in patients with poor performance 241
900
current management of 325 Cc
escalated M-VAC with GM-CSF 403 CA 125
neoadjuvant chemotherapy in 147 as indicator to treat ovarian cancer 257
second-line M-VAC 793 monoclonal antibody specific for 307
treatment with carboplatin and 5-FU 241 CA 153
treatment with carboplatin-containing regimen 313 as indicator in breast cancer 195, 807
bleomycin CAF
in follicular lymphoma 205 with or without MAP in adjuvant breast cancer 295
bone resorption cancer
and tamoxifen 683 and euthanasia 447, 794
bowel obstruction and fears 69
management of 15 and unorthodox therapy 121
percutaneous gastrostomy in 15 cancer care
brain metastases in developing countries 7, 263, 283
in small-cell lung cancer treated with chemotherapy only 579 cancer consultation
breast cancer role of letters and tapes 549
adjuvant chemohormonal therapy 295 cancer pain
and biologic prognostic factors 643 management 187, 267
and diet in Russia 495 cancer research
breast-conserving surgery, underutilization 96, 133 role of psychoneuroimmunology 714, 745
CA 153, 807, 861 CAPE/PALE
CAF with or without medroxyprogesterone acetate in adjuvant as salvage treatment in Hodgkin’s disease 857
treatment 295 carboplatin
CEA as tumor marker 861 and etoposide in good-risk germ cell tumors 663
c-erb-B2 as prognostic factors in advanced breast cancer 585, and etoposide in ovarian cancer 697
807 and etoposide in small-cell lung cancer 825
changing concepts in follow-up 199 and 5 FU in bladder cancer 245
combination of doxifluridine, prednimustine and idarubicin combinations in ovarian cancer S4: 41, $4: 83
423 containing regimen for bladder cancer 313
dose-intensity 351 ophthalmic toxicity of 337
drug resistance in 45 phase II study in breast cancer 303
endocrine therapy for 712, 735, 741 with cisplatin and ifosfamide in cervical cancer 485
epidemiology of 41 carcinogenesis
epirubicin in the treatment of 45, 359, 791 in renal cell cancer 451
5-FU and folinic acid in the treatment of advanced cases S2: cardiac tamponade
41 in ovarian cancer 896
follow-up 199 CEA
high-dose FEC in the treatment of 791 as marker in breast cancer 861
incidence and mammography 9, 41 CEMP
MDR in 11, 45 in non-Hodgkin’s lymphoma 172
mitoxantrone, 5-FU and leucovorin in the treatment of cervical cancer
advanced cases $2: 37 chemotherapy with ifosfamide, carboplatin and cisplatin 485
neu-oncogene and prognosis 585, 807 chemoprevention
phase II trial of iproplatin or carboplatin in 303 and nutrition 117
pre-operative chemotherapy with FEC 791 new preventive agents 117
prognostic significance of ploidy 213 overview of randomised trials 117
prognostic significance of proliferative activity 184, 213 chemotherapy
prognostic significance of tumor markers 807 a) combination
randomised comparison of tamoxifen, megestrol acetate or alternating combination in advanced gastric cancer 426
their combination in advanced cases 712, 741 CAF with or without medroxyprogesterone acetate in adjuvant
reversal of MDR in 11 breast cancer 295
risk factors in 41 CAPE-PALE as salvage treatment 857
routine follow-up in early breast cancer 199 CAPE-PALE as salvage treatment in Hodgkin’s disease 857
tamoxifen or medroxyprogesterone acetate in the therapy of Carbo-MVE for bladder cancer 313
advanced cases 712, 735 carboplatin and 5-FU in bladder cancer 241
TPA as tumor marker 861 carboplatin, cisplatin and ifosfamide in cervical cancer 485
treatment with epirubicin +/- verapamil 45 carboplatin combinations in ovarian cancer S4: 41, $4: 83
tumor markers 195, 807, 861 carboplatin-etoposide in good-risk germ cell tumors 663
verapamil for MDR in 45 carboplatin in breast cancer 303
busulfan carboplatin vs. cisplatin in ovarian cancer S4: 41
renal cancer after treatment 521 CEMP in non-Hodgkin’s lymphomas 172
CHOP-Bleo and interferon in follicular lymphoma 205 for high grade soft tissue sarcoma 509
cisplatin and 120-hour 5-FU in pancreatic cancer 333 gonadal function after intensive chemotherapy 399
cisplatin and etoposide in good-risk germ cell tumors 663 immunosuppression after purine analogues 347, 371
cisplatin combinations in ovarian carcinoma S4: 41, $4: 83 in hepatocellular carcinoma 489
CMV in bladder cancer 147 in Hodgkin’s disesae by HIV infection 621, 635
cyclophosphamide and glutathione in ovarian cancer 55 in the treatment of adenoid cystic carcinoma 785
doxifluridine, prednimustine and idarubicin in breast cancer in the treatment of gastrointestinal lymphomas 802, 831, 839
423 in the treatment of malignant fibrous histiocytoma of bone 409
E-SHAP in non-Hodgkin’s lymphomas 63, 896 in the treatment of non-small-cell lung cancer 804
etoposide and carboplatin in ovarian cancer 697 in the treatment of thymomas 429
FEC with dose-intensive epirubicin in breast cancer 791 LNH-87 protocol 651
FEMTX-P in gastric cancer 426 long-term results in ovarian cancer $4: 35
5-FU and folinic acid in breast cancer $2: 41 myocardial infarction after chemotherapy 432
5-FU and folinic acid in head and neck cancer $2: 45 new drugs based on topoisomerases 533
5-FU combined with [6S]-stereoisomer of folinic acid in of gallbladder carcinoma 607
colorectal cancer $2: 29 ophthalmic toxicity with carboplatin 337
5-FU, epidoxorubicin and cisplatin in gastric cancer 753 oral combination in breast cancer 423
5-fU, leucovorin and interferon in pancreatic cancer 83 oral treatment: its role in small-cell lung cancer 529
5-FU with tauromustine and leucovorin in colorectal cancer 81 randomised dose intensity study in ovarian carcinoma 377
M-VAC as second line in bladder cancer 793 results in bladder cancer 325
M-VAC escalated with GM-CSF in bladder cancer 403 results in Hodgkin’s disesae 385, 417
mitoxantrone, 5-FU and leucovorin in breast cancer $2: 37 role of chemotherapy in the treatment of ovarian cancer S4: 83
sequential methotrexate, 5-FU and leucovorin 235 role of pharmacology 463, 465, 466
suramin and mitomycin-c in prostatic cancer 567 salvage treatment in Hodgkin’s disease 657, 857
b) single agents stereoisomers of leucovorin $2: 7
carboplatin, phase II study in breast cancer 303 taxol in human ovarian carcinomas growing in the peritoneal
carboplatin vs. cisplatin in ovarian cancer S4: 41 cavity of nude mice 151
cisplatin: biweekly administration 221 toxicity of taxotere 610
cisplatin in bladder cancer 147 treatment of soft tisue sarcomas 669
cyclophosphamide in non-Hodgkin’s lymphomas 172 tumor markers as targets for new drugs 195
DuP 937 in malignant melanoma 695 children
DuP 937 in non-small cell lung cancer 693 ABMT in solid tumors S1: 45
edatrexate in melanoma 254 tropisetron in the control of nausea in $3: 35
epirubicin and ifosfamide in soft tissue sarcomas 669 chloroma
epirubicin in adenoid cystic carcinoma 785 as presenting relapse by AML 339
epirubicin in breast cancer 45 chromosome abnormalities
epirubicin ten years later 359 in secondary haematological malignancies after etoposide 559
etoposide in non-Hodgkin’s lymphomas 63, 172 in solid tumors 821
etoposide oral in adenocarcinomas of unknown origin 789 cisplatin
fludarabine in low-grade non-Hodgkin’s lymphomas 575 and 5-FU in 120-hour infusion in pancreatic cancer 333
fludarabine in refractory CLL 371 and etoposide in good-risk germ cell tumors 663
gemcitabine in renal cell cancer 331 and etoposide in the treatment of brain metastases 579
gemcitabine: in vivo activity in xenografts 157 as a continuous infusion 723
iproplatin, phase II study in breast cancer 303 combinations in ovarian cancer S4: 41, S4: 83
methotrexate in bladder cancer 147 cyclophosphamide and glutathione in ovarian cancer 55
mitoxantrone in non-Hodgkin’s lymphomas 172 high-dose in ovarian cancer 55, S4: 41
oral etoposide in ovarian cancer 517 its use in an anephric patient 679
oral etoposide in small-cell lung cancer 553 treatment of non-Hodgkin’s lymphomas 63
taxol in human ovarian carcinoma in nude mice 151 vs. carboplatin in ovarian cancer S4: 41
topotecan: Phase I 673 with carboplatin and ifosfamide in cervical cancer 485
vinblastine in bladder cancer 147 with 5-FU, folinic acid and epidoxorubicin in gastric cancer
c) general 753
and dose-intensity 349, 351, 377 clinical cases
and p53 623 bladder cancer 325
biochemical modulation 277, 317 fever and neutropenia 603
brain metastases treated with chemotherapy only 579 high grade soft tissue sarcoma 509
chemo-radiotherapy 94, 125, 256, 802, 804, 831, 847 Hodgkin’s disease 417
combination with radiotherapy in the treatment of non-small- mediastinal mass 781
cell lung cancer 804, 847 ovarian cancer 883
combination with suramin in prostatic cancer 567 tamoxifen and hypercalcaemia 683
concomitant radiotherapy and chemotherapy for gliomas 591 CLL
continuous infusions in cancer treatment 723 antitumor activity and immunosuppression of purine analogues
escalation of dose with GM-CSF 403 347
902
results with fludarabine in refractory cases 371 prognostic significance of ploidy in breast cancer 213
clodronate role of ploidy in ovarian carcinoma S4: 3
its use with tamoxifen 683 docetaxel (see taxotere)
severe hypocalcaemia after 432 dose intensity
clonal excess a review of concepts 23
prognostic relevance of non-Hodgkin’s lymphomas 393 and dose calculation 103
colony stimulating factor combined retrospective analysis of studies 103
escalated M-VAC with GM-CSF in bladder cancer 403 correlation with drug selection and scheduling 103
colorectal cancer correlation with outcome 23
chemotherapy of 81 in breast cancer 351
5-FU and interferon 515 in ovarian cancer 349, S4: 31, $4: 35, S4: 49, S4: 57, S4: 83
5-FU combined with [6S]-stereoisomer of folinic acid in the increase through biweekly cisplatin administration 221
treatment of $2: 29 its prognostic significance in non-Hodgkin’s lymphomas 651
5-FU with tauromustine in the treatment of 81 prospective studies 103
meta-analysis of trials with leucovorin S2: 15 doxifluridine
randomized comparison of 5-FU, leucovorin +/- methotrexate with idarubicin and prednimustine in breast cancer 423
235 doxorubicin
trial for adjuvant treatment in high-risk colorectal cancer $2: in continuous infusion 723
21 vs. epirubicin 359
unexpected fatal toxicity with 5-FU and leucovorin 174 drug discovery
combined modality tumor markers as targets 195
in the treatment of gastrointestinal lymphomas 802, 831, 839 drug resistance
in the treatment of gliomas 591 in breast cancer 9, 45
in the treatment of non-small-cell lung cancer 804, 847 in ovarian cancer S4: 57
in the treatment of ovarian cancer $4: 23, S4: 31, $4: 35, S4: DuP (see teloxantrone)
83
complementary therapy E
vs. unorthodox cancer therapy 121 E-SHAP
continuous infusion for refractory and relapsing lymphoma 63, 896
an appraisal of 5-FU, doxorubicin and platinums 723 edatrexate
120-hour infusion of 5-FU in pancreatic cancer 333 in melanoma: phase II 254
cross-resistance emotional distress
and dose-relationship in breast cancer 351 and low natural cytotoxic activity 714, 745
between epirubicin and doxorubicin 359 endocrine therapy
cisplatin vs. carboplatin S4: 41 with CAF in breast cancer 295
cyclophosphamide with tamoxifen, megestrol acetate. or their combination in
and inefficient drug metabolism 895 advanced breast cancer 712, 741
in non-Hogdkin’s lymphoma 172 with tamoxifen or medroxyprogesterone acetate in breast
with cisplatin and glutathione in ovarian cancer 55 cancer 712, 735
cyproterone acetate epidemiology
and hepatotoxicity 701 breast cancer risk and diet in Russia 495
cytogenetics epirubicin
and carcinogenesis in renal cell cancer 451 and cardiotoxicity 359
in secondary haematological malignancies after etoposide 559 and ifosfamide in soft tissue sarcomas 669
in solid tumors 821 in adenoid cystic carcinoma 785
cytokines ten years later 359
and oncogenes 35 with 5-FU, folinic acid and cisplatin in gastric cancer 753
in ovarian cancer $4: 71, $4: 83 with verapamil in breast cancer 9, 45
erbB2
D amplification in ovarian cancer 775
debulking surgery erythropoietin
and its role in ovarian cancer 264, 289, S4: 17, $4: 23, $4: 31, treatment of chronic anemia in tumors 161
S4: 83 ESMO
DEL 6q recognition of medical oncology 101
in diffuse lymphomas 51 survey of members 101
dexamethasone etiology
and tropisctron in the control of nausea and vomiting S3: 31 of ovarian cancer S4: 3
diet etoposide
content of fat and breast cancer risk in Russia 495 and carboplatin in ovarian cancer 697
differentiation and carboplatin in small-cell lung cancer 825
of small cell lung cancer cell lines by different agents 499 and cisplatin in the treatment of brain metastases 579
DNA and secondary haematological malignancies 559
aneuploidy 75 in the treatment of adenocarcinomas of unknown primary site
789 G
low-dose oral in ovarian cancer 517 gallbladder cancer
prolonged oral administration in small-cell lung cancer 529, phase I] trial of mitomycin-c 607
553 gastric cancer
treatment of non-Hodgkin’s lymphomas 63 after lymphoma 256
with cisplatin or carboplatin in good-risk germ cell tumors 663 high-dose MTX and 5-FU alternated with epirubicin and
euthanasia cisplatin 426
a comment 794 treatment with FLEP combination chemotherapy 753
a professional point of view 794 gastrointestinal lymphoma
in The Netherlands: fact and moral arguments 447 an unresolved question 802
combined modality for the treatment of 831
F treatment of primary gastric lymphoma 839
FEC gemcitabine
high-dose in breast cancer 791 in renal cell cancer 331
FEMTX-P in xenografts 157
in gastric cancer 426 germ cell tumors
fever cisplatin-etoposide and carboplatin-etoposide in the treatment
and neutropenia: management 603 of 663
fibronectin treatment for good-risk patients 663
as adhesion molecule 545 glioma
flow cytometry chemotherapy and concomitant radiotherapy 591
and its use in breast cancer as prognostic factor 643 glutathione
and its use in non-Hodgkin’s lymphomas 393 and cyclophosphamide in ovarian cancer 55
fludarabine GM-CSF
immunosuppression with 347 and escalted M-VAC in bladder cancer 403
in CLL 371 granisetron
in treatment of low-grade non-Hodgkin’s lymphomas 575 review of the experience with $3: 9
fluoropyrimidines growth factors (see also biological response modifiers)
modulation with leucovorin 277 and phase I trials methodology 471
scheduling of major representatives 277 urinary-derived P-100 877
fluorouracil
and interferon in colorectal cancer 515 H
combined with folinic acid in advanced breast cancer S2: 41 head and neck cancer
combined with folinic acid in the treatment of head and neck 5-FU and folinic acid in the treatment of S2: 45
cancer §2: 45 psychosocial problems 69
combined with mitoxantrone and leucovorin in breast cancer treatment with epirubicin of adenoid cystic carcinoma 785
$2: 37 hematopoietic recovery
combined with [6S]-stereoisomer of folinic acid in colorectal with IL-3 after high-dose cyclophosphamide 759
cancer $2: 29 hematopoietic support
in continuous infusion 723 in ovarian cancer S4: 49, $4: 57, $4: 83
in the treatment of malignant gliomas 591 hepatitis C
meta-analysis of trials with leucovorin S2: 15 late seroconversion in hematologic disorders 229
monitoring of modulation by a-IFN using magnetic resonance hepatocelluar carcinoma
597 prognostic factors in patients with 489
reversal of toxicity by oral uridine 317 hepatotoxicity
sequential combination with methotrexate +/- leucovorin in in the treatment with cyproterone acetate 701
colorectal cancer 235 high-dose chemotherapy
trials in high-risk resected colorectal cancers $2: 21 and biweekly cisplatin administration 221
unexpected fatal toxicity with low-dose leucovorin 174 and its use in breast cancer 351
with folinic acid, epidoxorubicin and cisplatin in gastre cancer hematopoietic recovery after IL-3 759
753 in aggressive lymphoma S1: 7
with leucovorin and interferon in pancreatic cancer 83 in breast cancer 23
with tauromustine and leucovorin in colorectal cancer 81 in low-grade lymphoma S1: |
folinic acid (see also leucovorin) in ovarian cancer $4: 49, $4: 57, S4: 83
and interferon in colorectal cancer 515 in relapsed Hodgkin’s disease S1: 21
meta-analysis of trials with leucovorin S2: 15 in solid tumors S1: 29
with 5-FU, epidoxorubicin and cisplatin in gastric cancer 753 in solid tumors of childhood S1: 45
with 5-FU in breast cancer $2: 4, $2: 37 in the primary treatment of Hodgkin’s disease S1: 15
with 5-FU in head-neck S2: 45 in the treatment of ALL S1: 81
follicular lymphomas (see lymphomas and non-Hogdkin’s in the treatment of AML S1: 59
lymphomas) MTX and 5-FU alternated with epirubicin and cisplatin in
904
gastric cancer 426 in the treatment of non-Hodgkin’s lymphoma 182, 205
review of concepts 23 intrapleural instillation 141
with FEC in breast cancer 791 modulation of 5-FU monitored by magnetic resonance 597
with hematopoietic rescue in Hodgkin’s disease 767 with 5-FU and leucovorin in pancreatic cancer 83
histiocytoma intrapleural therapy
chemotherapy of malignant fibrous histiocytoma of bone 409 instillation with interferon 141
HIV iproplatin
and Hodgkin’s disease 621, 635 phase II study in breast cancer 303
Hodgkin’s disease Italy
and its current management 417 teaching of clinical oncology 717
and prognostic factors 385
and second malignancies 94, 125 L
and secondary cancer 520 leucovorin
chemotherapy in HIV-cases 621, 635 and interferon in colorectal cancer 515
correlation with cell proliferation 75 combined withS-FU in advanced breast cancer $2: 41
correlation with DNA aneuploidy 75 combined with 5-FU in the treatment of head and neck cancer
current management 417 $2: 45
early relapses 857 combined with mitoxantrone and 5-FU in breast cancer $2: 37
high-dose chemotherapy with hematopoietic rescue 767, 889 different isomers 277
high-dose sequential chemo-radiotherapy 889 meta-analysis of trials with 5-FU $2: 15
in HIV infection 621, 635 pharmacokinetics of stereoisomers $2: |
in i.v.-drug users 621, 635 role of different stereoisomers $2: 7
late relapses 657 unexpected fatal toxicity in combination with 5-FU 174
long term results 385 with 5-FU and interferon in pancreatic cancer 83
prognosis of 75 with 5-FU and tauromustine in colorectal cancer 81!
prognostic factors after high-dose chemotherapy 767 leukemia
role of ABMT in primary cases $1: 15 acute promyelocytic variant in Nicaragua 892
role of ABMT in relapsed cases S1: 21 dose intensity 23
role of progenitor cell support in relapsed cases 889 general management of 631
salvage therapy 385, 857 new research questions 631
salvage treatment 889 liver cirrhosis
salvage treatment in early disease 857 and hepatitis C in haematologic disorders 229
salvage treatment in late relapses 657, 857 and malignant lymphoproliferative disorders 245
second malignancies, after ABVD chemotherapy 94 lung cancer
second malignancies, after MOPP chemotherapy 94 activity of gemcitabine in xenografts treated with gemcitabine
second malignancies, correlation with age 125 157
second malignancies, correlation with treatment intensity 125 brain metastases from small-cell lung cancer treated with
hypercalcaemia chemotherapy only 579
under tamoxifen 683 carboplatin and etoposide 877
combined treatment with chemo-radiotherapy for NSCLC 804,
I 847
idarubicin differentiation of small cell lines by different agents 499
with prednimustine and doxifluridine in breast cancer 423 dose intensity 23
ifosfamide DUP 937 in NSCLC 693
and epirubicin in soft tissue sarcomas 669 in HIV patients 85
with carboplatin and cisplatin in cervical cancer 485 non-small cell, phase II of DuP 937 693
IL-2 P-100 derived growth factor in the treatment of 877
as a continuous infusion in renal cell cancer 689 role of oral etoposide in the treatment of small-cell lung cancer
IL-3 529, 553
after high-dose cyclophosphamide 759 lymphoma(s) (see also non-Hodgkin’s lymphomas)
immunosuppression and liver cirrhosis 245
after treatment with fludarabine 371 CEMP in the treatment of 172
after treatment with purine analogues 347, 371 cytogenetics 51, 825
and seroconversion of hepatitis C virus 229 etoposide in the treatment of 63
infections fludarabine in the treatment of 575
after fludarabine for low-grade lymphoma 575 follicular lymphoma 182, 825
after treatment with fludarabine in CLL 371 gastrointestinal lymphoma 802, 831, 839
in immunosuppression due to purine analogues 347 immunoblastic and BCL-2 rearrangement 51
integrin large cell and BCL-2 rearrangement 51
as adhesion molecule 545 prognostic index in high grade 853
interferon(s) role of E-SHAP in refractory cases 63, 896
and folinic acid in colorectal cancer 515 role of interferon 182
for malignant pleural effusions 141 transformation in low-grade lymphomas 825
treatment with CHOP-Bleo and interferon 205 rearrangement of bcl-2 51
lymphoproliferative diseases topoisomerases as target for new anticancer drugs 533
and multistep tumorigenesis 825 monoclonal antibodies
MLDUS 825 In-111-labeled specific for CA125 307
myeloma
M dose intensity 23
M-VAC myocardial infarction
as second line in patients previously treated with the same after chemotherapy for testicular teratomas 432
regimen 793 unexpected fatal toxicity with low dose leucovorin/S5-FU 174
escalated with GM-CSF in bladder cancer 403
MACOP-B N
and gonadal function in patients with non-Hodgkin’ s natural killer cells
lymphoma 399 and emotional distress 714, 745
magnetic resonance nausea (see also antiemetics)
intratumoral pharmacokinetic of gemcitabine in xenografts 157 current management S3: 3
monitoring biochemical modulation of 5-FU and a-IFN 597 in children: role of tropisetron $3: 35
MALT lymphoma prophylaxis of nausea with oral ondansetron 475
and follicular lymphoma 182 role of tropisetron in gynecological patients $3: 47
in the gastrointestinal tract 802, 831, 839 role of tropisetron in patients resistant to conventional
mammography antiemetic therapy S3: 25
and overdiagnosis of breast cancer 9 tropisetron and dexamethasone in the control of $3: 31
cancer detection by 41 neutropenia
MDR its management during intensive chemotherapy 603
and p-glycoprotein | 1 new drugs
mechanism of action and their role in ovarian cancer $4: 63, $4: 79
carcinogenesis 451 Nicaragua
of adhesion molecules 545 acute promyelocytic leukemia in 892
of p-glycoprotein 11 developing oncologic project in 37
p53 as a target for anticancer drugs 623 non-Hodgkin’s lymphomas (see also lymphomas)
topoisomerases 533 chemotherapy in elderly patients 172
mediastinal mass fludarabine in treated and untreated patients 575
current management 781 interferon in the treatment of follicular lymphomas 182, 205
medical oncology prognostic impact of clonal excess 393
teaching of, in Italy 717 prognostic significance of dose intensity 651
medroxyprogesterone acetate (MAP) role of ABMT in aggressive cases $1: 7
combined with CAF in adjuvant breast cancer 295 role of ABMT in low-grade cases S1: 1
or tamoxifen in advanced breast cancer 712, 735 salvage chemotherapy 63, 251
megestrol acetate nude mice
or tamoxifen or their combination in advanced breast cancer activity of gemcitabine in small-cell lung cancer 157
712, 741 antitumor activity of taxotere in ovarian cancer 321
melanoma treatment with taxol in ovarian carcinoma 151
human antigen 35 nutrition
phase II of DuP 937, 695 and breast cancer 495
phase II study of edatrexate 254 and chemoprevention 117
meta-analysis
in ovarian cancer S4: 23, $4: 79 O
of 5-FU and leucovorin $2: 15 oncogenes
metabolism and chromosome abnormalities in solid tumors 821
of cyclophosphamide and bone marrow toxicity 895 and cytokines 35
methotrexate erbB2 amplification in ovarian cancer 775
in bladder cancer 147 role in transformation of low-grade lymphomas 825
modulation with leucovorin stereoisomers $2: 1 role of bel-2 51
sequential with 5-FU and leucovorin 235 oncology
mitomycin-c in developing countries 7, 263, 283
combined with suramin in prostatic cancer 567 teaching of, in Italy 717
phase II in gallbladder 607 ondansetron
mitoxantrone a randomised trial vs. placebo in patients treated with CMF
combined with 5-FU and leucovorin in breast cancer $2: 37 475
in lymphomas 172 review of the experience with S3: 9
molecular biology opioid
and adhesion molecules 545 drugs in cancer pain 267
and cytogenetics in solid tumors 821 oral
of transformation in low-grade lymphomas 825 etoposide 63, 517, 529, 553
906
three-drugs combination in treatment of breast cancer 423 591
ovarian carcinoma the relevance of pharmacology in clinical oncology practice
activity of taxol in xenografts 151 463, 465, 466
and surgical procedure 264, 289, S4: 17, S4: 23, S4: 83 phase I
antitumor activity of taxotere in cell lines 321 are hematopoietic growth factors changing the methodology?
biological role of oncogenes 775, S4: 3 471
CA125 in S4: 71 5-FU and oral uridine 317
carboplatin versus cisplatin S4: 41 of MDL 73.147 EF: a new 5-HT,-receptors antagonist 481
cardiac tamponade in 896 topotecan 673 j
consensus statements S4: 83 phase II
epidemiological aspects 264, 289 carboplatin in breast cancer 303
erb-B2 amplification 775 cisplatin and 120-hour 5-FU in pancreatic cancer 333
etiology of S4: 3 DuP 937 in malignant melanoma 695
etoposide and carboplatin in the treatment of 697 DuP 937 in non-small cell lung cancer 693
immunoscintigraphy for detection of recurrence 307 gemcitabine in renal cell cancer 331
long term results $4: 35 iproplatin in breast cancer 303
management of 883 of epirubicin in adenoid cystic carcinoma 785
meta-analyses in S4: 79 of etoposide in adenocarcinomas of unknown origin 789
new drugs in the treatment of S4: 63, S4: 83 of ifosfamide, carboplatin and cisplatin in cervical cancer 485
overexpression of 185, 775 of mitomycin-c in gallbladder cancer 607
pathogenesis of S4: 3 of oral combination of doxifluridine, pr«dnimustine and
prognostic factors $4: 3, $4: 23, $4: 31, $4: 35, S4: 79, S4: 83 idarubicin in breast cancer 423
randomised dose intensity study 377 of suramin and mitomycin-c in prostatic cancer 567
results with oral etoposide 517 oral etoposide in ovarian cancer 517
role of drug resistance S4: 57 oral etoposide in small cell lung cancer 553
second-line treatment in S4: 83 recombinant IL-2 in renal cell cancer 689
second-look laparotomy 169 platinum (see carboplatin, cisplatin, iproplatin)
survival after cisplatin treatment 264, 289 pleural effusions
the impact of dose-intensity 23, 349, 377, S4: 49, S4: 57 interferon instillation for the treatment of malignant effusions
tumor markers in $4: 71, S4: 83 141
ploidy
P prognostic significance in breast cancer 213
P-100 role in ovarian cancer S4: 3
as urinary-derived growth factor 825 prednimustine
P-glycoprotein with doxifluridine and idarubicin in breast cancer 423
and MDR 11 progenitor cell support
p53 for relapsed Hodgkin’s disease 889
as a target for new anticancer drugs 623 prognostic factors
p18s5 and results with E-SHAP in refractory lymphomas 63, 896
overexpression in ovarian cancer 775 aneuploidy and DNA index in breast cancer 643
pancreatic cancer dose intensity in non-Hodgkin’s lymphoma 651
chemotherapy 83 in bone marrow transplantation for Hogdkin’s disease 767
phase II of cisplatin and 120-hour 5-FU 333 in hepatocellular carcinoma treated with chemotherapy 489
patient-care in high grade lymphomas 853
doctors’ views on letters and tapes 549 in ovarian cancer $4: 3, $4: 23, $4: 31, $4: 71, $4: 79, $4: 83
pediatric oncology neu-oncogene in advanced breast cancer 585
in developing countries 37 tumor markers in breast cancer 195, 807
peripheral stem-cell transplantation (see also progenitor cell prognostic index
support) in high grade lymphomas 853
after high-dose chemotherapy in Hodgkin’s disease 767 proliferative activity
pharmacokinetic(s) available measurements 184
and metabolism for high-dose cyclophosphamide 895 prognostic significance in breast cancer 213
dose intensity 23 role in clinical oncology 184
of biweekly cisplatin administration 221 promyelocytic leukemia
of cisplatin in an anephric patient 679 increased incidence in childhood in Nicaragua 892
of fluoropyrimidines 277 prostate cancer
of 5-FU with interferon 515 results with suramine combined with mitomycin-c 567
of leucovorin stereoisomers $2: | psycho-oncology
of opioid drugs in cancer pain 267 and alternative therapies 121
of oral etoposide in small-cell lung cancer 553 in familial cancer 714, 745
of topotecan 673 psycho-social problems in head and neck cancer 69
of tropisetron $3: 15 psycho-neuroimmunology
pharmacology of 5-FU, hydroxyurea and iododeoxyuridine in familial cancer and emotional distress 714, 745
purine analogues current state-of-the art for leucovorin $2: 7
antitumor activity in CLL 347, 371 of leucovorin and their pharmacokinetics $2: 1
in the treatment of lymphomas 393 suramin
combined with mitomycin-c in prostatic cancer 567
Q surgery
quality-of-life and its role in ovarian cancer 69, 264, 289, 857, S4: 17, $4: 23,
and clinical trials 520 S4: 31, $4: 83
and unorthodox cancer therapy 121 breast conserving, underutilization 96, 133
influence of the type of surgical treatment for breast cancer
133 T
in patients with head-and-neck cancers 69 tamoxifen
and hypercalcaemia 683
R randomised trial vs. medroxyprogesterone acetate in advanced
racemic form breast cancer 712, 735
of leucovorin and its role S2: 1 vs. megestrol acetate or in combination with megestrol acetate
radiotherapy in advanced breast cancer 712, 741
and chemotherapy in gastrointestinal lymphomas 802, 831, tauromustine
839 with 5-FU and leucovorin 81
combined with chemotherapy for malignant gliomas 591 taxol
combined with chemotherapy in non-small-cell lung cancer in Ovarian carcinoma in nude mice 151
804, 847 taxotere
in Hodgkin’s disease during HIV infection 635 antitumor activity in experimental ovarian cancer 321
its role in ovarian cancer S4: 83 preventive treatment of toxicities 610
randomized trial teaching
CAF with or without MPA in adjuvant breast cancer 295 of clinical oncology in Italy 717
carboplatin vs. cisplatin in ovarian cancer S4: 41 teloxantrone
comparison of 5-FU, leucovorin, +/- methotrexate 235 phase II trial in malignant melanoma 695
of different dose intensity in ovarian cancer 377 phase II trial in non-small cell lung cancer 693
of endocrine agents in breast cancer 712, 735, 742 terminal cancer patients
iproplatin vs. carboplatin in breast cancer 303 palliative treatment in 15
with/without verapamil in breast cancer 45 with bowel obstruction 15
renal cell cancer testicular cancer
after busulphan treatment 521 cisplatin-etoposide and carboplatin-etoposide in the treatment
and cytogenetics 451 of 663
continuous infusion of IL-2 in the treatment of 689 myocardial infarction after chemotherapy 432
phase II of gemcitabine 331 paratesticular rhabdomyosarcomas in adults 871
role of carcinogenesis 451 treatment for good-risk patients 663
renal function thymomas
cisplatin in anephric patient 679 results with chemotherapy 429
rhabdomyosarcoma topoisomerase
paratesticular localisation in adults 871 as target for new anticancer drugs 533
topotecan, a new topoisomerase I inhibitor 673
S topotecan
S-phase fraction phase I of 673
as prognostic parameter in breast cancer 643 toxicity
salvage treatment of tamoxifen 683
in Hodgkin’s disease with early relapses 857, 889 of taxotere, preventive treatment 610
in Hodgkin’s disease with late relapses 657 ophthalmic complication with carboplatin 337
with etoposide and carboplatin in ovarian cancer 697 unexpected fatal toxicity of low-dose leucovorin/S-FU 174
sarcoma TPA
chemotherapy of malignant fibrous histiocytoma of bone 409 as tumor marker in breast cancer 861
second cancer tropisetron
after busulfan treatment 521 and its role in antiemetic treatment $3: 1
after etoposide treatment 559 combined with dexamethasone in the control of vomiting S3:
second-look laparotomy 31
in the management of ovarian cancer 169 experience with its compassionate use S3: 43
soft tissue sarcomas its development $3: 19
current management 509 its role as antiemetic in children $3: 35
epirubicin and ifosfamide in the treatment of 669 its role in gynecological patients $3: 47
paratesticular rhabdomyosarcomas in adults 871 pharmacology and toxicology of S3: 15
solid tumors role of, in patients resistant to conventional antiemetic therapy
role of cytogenetics 821 $3: 25
stereoisomers the Nordic experience $3: 39
908
tumor immunology with epirubicin in breast cancer 11, 45
and cytokines 35 vinblastine
tumor markers in bladder cancer 147
and their role in breast cancer 195, 807 vomiting
and their role in ovarian cancer $4: 71, $4: 83 current issues in its management $3: 3
CA125 in ovarian cancer 257, $4: 71 role of tropisetron as a new antiemetic S3: |
CA153 861 role of tropisetron in patients at risk of severe emesis $3: 43
CEA in breast cancer 861 treatment with tropisetron in children $3: 35
TPA in breast cancer 861 treatment with iropisetron in gynecological patients $3: 47
tumor suppressor genes tropisetron and dexamethasone in the treatment of S3: 31
and cytogenetics in solid tumors 821 VP-16 (see etoposide)
p53 as a target for new drugs 623
their role in transformation of low-grade lymphomas 825 x
xenografts
U activity of gemcitabine in small cell lung cancer 157
uridine antitumor activity of taxotere in ovarian cancer 321
and its use in reversing 5-FU toxicity 317 of human ovarian carcinoma treated with taxol 151
Vv Y
VACOP-B Yolk sac tumor
gonadal function in patients with non-Hodgkin’s lymphomas and cardiac tamponade 896
399
venous access Z
migration of implantable infusion catheter 173 zidovudine
verapamil in AIDS and HD 621, 635
and MDR 11